BidaskClub cut shares of NuVasive (NASDAQ:NUVA) from a hold rating to a sell rating in a research report report published on Tuesday, BidAskClub reports.

A number of other research analysts have also recently commented on the stock. Zacks Investment Research cut shares of Guaranty Federal Bancshares from a hold rating to a sell rating in a research report on Tuesday, April 23rd. Cantor Fitzgerald reiterated a buy rating and set a $25.00 price target on shares of Menlo Therapeutics in a research report on Thursday, May 2nd. BTIG Research cut shares of EVO Payments from a buy rating to a neutral rating in a research report on Monday, July 1st. Finally, ValuEngine cut shares of USD Partners from a hold rating to a sell rating in a research report on Friday, June 14th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have assigned a buy rating to the company. NuVasive currently has an average rating of Hold and a consensus price target of $66.79.

Shares of NUVA opened at $57.07 on Tuesday. The company has a 50 day moving average of $58.31. The stock has a market capitalization of $2.97 billion, a P/E ratio of 24.22, a P/E/G ratio of 2.10 and a beta of 1.11. The company has a debt-to-equity ratio of 0.80, a current ratio of 3.75 and a quick ratio of 1.96. NuVasive has a 1-year low of $43.51 and a 1-year high of $72.41.

NuVasive (NASDAQ:NUVA) last announced its earnings results on Wednesday, May 1st. The medical device company reported $0.53 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.12. The business had revenue of $274.78 million for the quarter, compared to the consensus estimate of $269.22 million. NuVasive had a net margin of 4.39% and a return on equity of 15.16%. NuVasive’s quarterly revenue was up 5.5% on a year-over-year basis. During the same period last year, the firm posted $0.39 earnings per share. As a group, research analysts anticipate that NuVasive will post 2.28 EPS for the current year.

In other news, President Matthew Link sold 10,100 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $62.00, for a total value of $626,200.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.97% of the stock is currently owned by company insiders.

Several institutional investors have recently modified their holdings of NUVA. Royce & Associates LP bought a new position in shares of NuVasive in the fourth quarter worth approximately $25,000. Bessemer Group Inc. bought a new position in shares of NuVasive in the fourth quarter worth approximately $50,000. Rockefeller Capital Management L.P. grew its holdings in shares of NuVasive by 251.2% in the first quarter. Rockefeller Capital Management L.P. now owns 2,002 shares of the medical device company’s stock worth $114,000 after purchasing an additional 1,432 shares during the last quarter. Knott David M bought a new position in shares of NuVasive in the first quarter worth approximately $114,000. Finally, Zions Bancorporation N.A. bought a new position in shares of NuVasive in the first quarter worth approximately $175,000.

About NuVasive

NuVasive, Inc, a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.

Further Reading: Understanding Analyst Recommendations

Analyst Recommendations for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.